Processa Pharmaceuticals Inc. (PCSA)
PCSA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1533743/000149315223009730/0001493152-23-009730-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PCSA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001533743 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2022
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$27.4M |
| Operating income | -$27.5M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $6.5M |
| Total assets | $8.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Accordingly, we concluded that substantial doubt about our ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued." | 10-Q 2026-11-13 |
| Cash and burn | $196K cash; operating cash flow -$3.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 2,798,241 (2026-11-09); 56,644,223 a year earlier; 24,631,474 three years earlier. 1y figure adjusted for splits (1-for-25 overall); 3y figure adjusted for splits (1-for-500 overall). | Cover page 2026-11-09 |
| Reverse splits, 3 years | 2; latest 1-for-25 on 2025-12-17 | Source 2025-12-17 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-10-09 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Cherry Bekaert LLP, Tampa, Florida, United States | PCAOB Form AP 2026-03-19 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $209K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$3.3M | -$2.0M | $196K | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$3.4M | -$3.6M | $1.7M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$3.4M | -$2.9M | $5.5M | No debt tags | Needs four quarters | 10-K 2026-03-18 |
| Q3 2025 2025-09-30 | Not filed | -$3.4M | -$3.5M | $6.3M | No debt tags | Needs four quarters | 10-Q 2025-11-06 |
| Q2 2025 2025-06-30 | Not filed | -$3.9M | -$2.3M | $6.9M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$2.8M | -$2.7M | $2.9M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$2.7M | -$2.2M | $1.2M | No debt tags | Needs four quarters | 10-K 2026-03-18 |
| Q3 2024 2024-09-30 | Not filed | -$3.4M | -$3.6M | $2.9M | No debt tags | Needs four quarters | 10-Q 2025-11-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-10-09 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-11-05 |
Source: SEC EDGAR submissions feed, 706 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.6% |
| 1 month | +5.1% |
| 3 months | -25.6% |
| Year to date | -35.4% |
| 1 year | -74.5% |
| From 52-week high | -75.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PULM | Pulmatrix Inc. | $1.33 | +2.31% | $4.9M |
| CANF | Can-Fite Biopharma Ltd | $1.56 | +9.86% | $4.7M |
| SCNX | Scienture Holdings Inc. | $2.99 | +3.10% | $4.9M |
| SKYE | Skye Bioscience Inc. | $1.06 | -2.29% | $4.7M |
| CVKD | Cadrenal Therapeutics Inc. | $1.40 | -7.28% | $5.0M |
| CNSP | CNS Pharmaceuticals Inc. | $3.48 | +20.42% | $5.1M |
| JAGX | Jaguar Health Inc. | $0.3864 | -7.74% | $5.2M |
| NCNA | NuCana plc American Depositary Share | $0.8631 | -7.46% | $4.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier